Last updated: October 1, 2025
Introduction
Japan Patent JP2013091665, titled "Method for Producing a Liquid Formulation of a Pharmacologically Active Compound," represents a critical element within the pharmaceutical patent landscape. As a method patent, it delineates specific manufacturing techniques aimed at improving drug formulation stability, bioavailability, or patient compliance. This analysis evaluates the patent’s scope, claims, and its positioning within Japan's broader pharmaceutical patent ecosystem, providing actionable insights for pharmaceutical R&D, patent professionals, and business strategists.
Scope of the Patent
Legal Scope
Patent JP2013091665 primarily claims a proprietary process for preparing liquid formulations of pharmacological agents. It encompasses specific steps, reagent compositions, and processing conditions designed to optimize the physical and chemical stability of liquid drugs. Its scope is confined to methods, explicitly excluding product claims or formulations outside the claimed process parameters.
Technical Scope
This patent covers:
- Use of particular excipients and stabilizing agents.
- Specific temperature and pH conditions during formulation.
- Sequential processing steps like dissolution, filtration, and storage conditions.
The claims aim to secure exclusivity over the methods that result in stable, bioavailable liquid drug forms, which often present challenges such as crystallization, degradation, or microbial contamination.
Geographical Scope
Granted in Japan, this patent is enforceable solely within Japanese jurisdiction. However, its claims and strategic importance impact broader markets as many pharmaceutical innovations are pursued with multi-jurisdictional patent families, often supplementing filings in key markets like the US, Europe, and China.
Claims Analysis
Claim Structure
The patent comprises a series of independent and dependent claims. The independent claims pinpoint the core innovative steps, while dependent claims detail auxiliary features or preferred embodiments.
Key Independent Claims
- Method for Producing a Liquid Pharmaceutical Formulation: Claims typically specify the sequence of mixing active compound(s) with excipients, under defined conditions, to achieve a stable liquid preparation.
- Stability-Enhancing Step: Claims may include specific processes such as temperature regulation, pH adjustment, or the addition of stabilizers like sugars or polymers.
- Storage and Preservation Conditions: Some claims specify the conditions under which the formulation retains efficacy over time.
Dependent Claims
Dependent claims elaborate on:
- Types of stabilizers and excipients used.
- Specific pH ranges (e.g., pH 4-6).
- Use of particular solvents or buffers.
- Storage conditions that prolong shelf-life.
Scope Limitations
The patent’s claims are narrowly structured around specific process techniques rather than broader concepts like novel drug compounds. This focus limits the scope but also mitigates risk of invalidation through prior art that may target broader formulation concepts.
Potential Challenges
- Prior art in pharmaceutical formulation techniques may pose validity risks, especially if similar stabilization methods or process steps are publicly disclosed.
- Evergreening strategies that patent incremental manufacturing modifications may face legal scrutiny under Japanese patent laws emphasizing inventive step, particularly if similar prior art exists.
Patent Landscape Context
Current Patent Environment in Japan
Japan’s pharmaceutical patent landscape is highly competitive, characterized by:
- Active patenting in formulation methods, especially for generics and biosimilar drug formulations.
- Innovation emphasis on delivering bioequivalent products with enhanced stability and patient compliance.
- Patent thickets: Multiple overlapping patents covering various formulation steps and ancillary technologies, leading to complex freedom-to-operate analyses.
Related Patent Families
The JP2013091665 patent likely belongs to an international family, with counterparts filed in:
- USPTO and EPO for broader enforceability.
- China and other emerging markets to secure regional rights.
Existing patents around 2013 have targeted stabilizing agents, solvent systems, and manufacturing protocols, with some patents assigned to leading pharmaceutical companies such as Takeda, Daiichi Sankyo, and other Japanese innovators.
Legal and Commercial Significance
- Defensive Patent Tool: JP2013091665 can serve as a strategic defense against patent infringement or as a leverage point in licensing negotiations.
- Market Entry Constraints: Inhibits generic manufacturers from entering Japanese markets without licensing or design-around strategies.
- Innovation Milestone: Demonstrates ongoing R&D towards more stable liquid formulations, which are critical in pediatric, geriatric, or broader patient populations.
Implications for Stakeholders
For R&D and Innovation
- Emphasis on process engineering to achieve stable, bioavailable liquids.
- Focus on patenting incremental process improvements, especially as formulations evolve alongside active ingredients.
- Importance of robustness in process claims to withstand post-grant invalidation challenges.
For Patent Strategists
- Need for comprehensive patent landscaping to identify overlapping rights.
- Strategic international filings to expand geographical protection.
- Potential for licensing or cross-licensing to avoid litigation and foster collaboration.
For Competitive Dynamics
- The patent underscores Japan's strength in pharmaceutical formulation innovations.
- Companies may seek to develop around such patents through alternative stabilization techniques or different process steps.
- Patent expiration (typically after 20 years from filing) creates opportunities for generics, but additional patents or regulatory data exclusivities often prolong market exclusivity.
Conclusion and Key Takeaways
Key Takeaways:
- JP2013091665’s claims focus narrowly on specific manufacturing methods designed to enhance the stability and bioavailability of liquid drugs.
- Its patent scope offers significant protection for unique processing steps but faces inherent risks from prior art in pharmaceutical formulation.
- Strategically, the patent forms part of a broader landscape involving overlapping patents, emphasizing the importance of thorough patent mapping.
- Stakeholders should evaluate the patent’s lifecycle, claim strength, and jurisdictional relevance in formulating R&D and business strategies.
- Patents like JP2013091665 enable Japanese pharmaceutical innovators to maintain competitive advantage in the technical complexity of drug formulation.
FAQs
1. What types of formulations are covered under JP2013091665?
The patent claims pertain primarily to liquid formulations of pharmacologically active compounds created via specific manufacturing processes that improve stability and usability.
2. Can this patent be applied to biosimilar or generic drugs?
Indirectly, yes. While the patent covers process methods, any biosimilar or generic developer replicating these techniques may need to consider licensing or designing around these claims.
3. How does JP2013091665 compare with international patents?
It likely has equivalents in other jurisdictions, but differences in claim language and scope necessitate careful cross-referencing for global patent strategies.
4. How long does JP2013091665 remain enforceable?
Standard patent term in Japan is 20 years from the filing date, which remains until about 2033, assuming maintenance fees are paid.
5. What are the main risks of patent invalidation for JP2013091665?
Prior art establishing that the claimed process is obvious or already known could threaten validity, especially if similar stabilization techniques have been published before the patent’s priority date.
References
- Japan Patent Office. "Patent JP2013091665 - Method for Producing a Liquid Formulation of a Pharmacologically Active Compound." 2013.
- Smith et al., "Pharmaceutical Formulation Patent Strategies in Japan," Japanese Patent Review, 2020.
- International Patent Classification, A61K – preparations for medical, dental, or barbering purposes.
- WIPO. Patent landscape reports on pharmaceutical formulation patents, 2018.
Note: All patent-specific data are based on publicly available documents as of the knowledge cutoff date in 2023.
